May 12, 2026
StemRIM Inc.

StemRIM Announces the Progress for "Regeneration-Inducing Medicine™" Redasemtide

Osaka, Japan, May 12, 2026 – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; "StemRIM" or the "Company") announced today that Shionogi & Co., Ltd. (TSE:4507, Representative Director, Chairman of the Board and CEO: Isao Teshirogi; "Shionogi"). has disclosed its future research and development schedule for Redasemtide (development code: S-005151), a peptide drug candidate derived from HMGB1[1] and out-licensed by StemRIM as a "Regeneration-Inducing Medicine™" candidate.

Shionogi is currently conducting an additional Phase 2 clinical trial of Redasemtide for Dystrophic Epidermolysis Bullosa (DEB), as well as a global late Phase 2 clinical trial for Acute Ischemic Stroke (AIS).

For the additional Phase 2 clinical trial for DEB, Shionogi expects to release a preliminary summary of the results by September 2026, file for marketing approval in Japan in the second half of fiscal 2026 (October 2026 to March 2027), and launch the product in fiscal 2027 (April 2027 to March 2028).

For the global late Phase 2 clinical trial for AIS, Shionogi expects to release a preliminary summary of the results by September 2026, with a projected launch period of April 2028 to March 2031.

For further details, please refer to document [2] disclosed by Shionogi.

The Company will promptly disclose further information regarding each development milestone as soon as additional details become available.

[1] HMGB1 (High Mobility Group Box 1): one of the nuclear proteins that induces the migration of endogenous mesenchymal stem cells to sites of tissue injury.

[2] "Fiscal 2025 Financial Results" dated May 12, 2026 (Shionogi)

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with ectomesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
X: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)